PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

NCT05697198 · clinicaltrials.gov ↗

COMPLETED

Status

1429

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer
Ovarian Cancer
Uterine Cancer
Colorectal Cancer
Stomach Cancer
Esophageal Cancer
Pancreatic Cancer
Melanoma
Breast Cancer
Head and Neck Cancer
Soft Tissue Sarcoma
Rhabdomyosarcoma
Prostate Cancer

Interventions

DIAGNOSTIC_TEST: OmniSeq Test

Sponsor

Labcorp Corporation of America Holdings, Inc